Glen Bradley, PhD, MBA, has joined the Alimera Sciences Board of Directors and its audit committee.
Atlanta-Glen Bradley, PhD, MBA, has joined the Alimera Sciences Board of Directors and its audit committee.
Dr. Bradley is a consultant and adviser to ophthalmic and non-ophthalmic medical device companies. He was an executive officer of Novartis AG, Basel, Switzerland, from 1996 to 2003; chief executive officer (CEO) of CIBA Vision Group in Atlanta and Zurich from 1990 to 2003; and president and CEO of CIBA Vision Corp. in Atlanta from 1986 to 1989. Early in his career, Dr. Bradley worked for several different divisions of CIBA-Geigy Corp.
“We are honored to welcome such a respected industry leader to serve on our board,” said Dan Myers, president and CEO of Alimera. “Dr. Bradley’s wealth of knowledge, experience, and financial expertise in the ophthalmic industry will be invaluable in helping to guide Alimera Sciences’ future growth and development strategies.”
As a board member and audit committee member, Dr. Bradley replaces Anders D. Hove, MD, a partner with venture capital firm Venrock Associates, who resigned as a member of the board after 6 years. Bryce Youngren, already a member of Alimera’s board, replaced Dr. Hove as a member of the board’s compensation committee.